We are thrilled to announce that PRECISIONadvisors is now known as Precision AQ. By joining forces with over 1,200 experts across 100+ diverse fields, we aim to continue transforming the trajectory of the clients we serve while empowering access to life-changing therapies for all. Follow our new page, Precision AQ, to learn more about our new blueprint for access.
关于我们
PRECISIONadvisors, a Precision Value & Health team, is a global life sciences consultancy combining cutting-edge strategic and analytic capabilities. We pair best-in-class consulting expertise with hands-on industry and customer experience to guide launch excellence in biopharmaceutical innovation. Our team excels at understanding the ever-changing and complex healthcare market and helping clients solve high-visibility issues such as early pipeline planning, commercialization strategy, pricing and market access strategy, distribution strategy, patient support services design, and product value proposition. Engineered to shift the trajectory, we collaborate across the Precision Value & Health family to seamlessly bring specialized expertise to every junction of the innovation and commercialization continuum. We are currently seeking qualified candidates to join our team. To learn more about opportunities in our US and Europe offices please go to careers.precisiongroupcompanies.com.
- 网站
-
https://www.precisionadvisors.com
PRECISIONadvisors的外部链接
- 所属行业
- 商务咨询服务
- 规模
- 501-1,000 人
- 总部
- New York,NY
- 类型
- 私人持股
地点
PRECISIONadvisors员工
动态
-
Precision has a busy conference schedule this month. Let's connect! PRECISIONvalue PRECISIONheor PRECISIONadvisors PRECISIONxtract PRECISIONscientia PRECISIONeffect
-
-
The FDA’s Accelerated Approval process has transformed cancer treatment timelines, providing a beacon of hope to patients in their toughest battles. With controversies surrounding drugs like aducanumab and regulatory shifts, we’re delving into what this signifies for the future of pharma. Join the conversation with Ross Maclean and Michael Glover in PharmaLive to explore the full article’s insights. #FDA #oncology #acceleratedapprovals #biopharma #FDAapproval #Patientoutcomes PRECISIONvalue PRECISIONheor PRECISIONadvisors
-
-
Asian American and Pacific Islander (AAPI) Heritage Month starts today, and Precision honors 2 healthcare trailblazers who are making a fundamental difference in people’s lives. Our congratulations and thanks go to Dr. Vivek Murthy, Surgeon General of the United States, and Dr. Joy Shu Jiang, whose research into breast cancer risk prevention addresses racial disparities. #AAPI #AsianAmericanAndPacificIslanderHeritageMonth #TrailblazingHealthcare PRECISIONvalue PRECISIONadvisors PRECISIONxtract PRECISIONheor PRECISIONeffect PRECISIONscientia
-
-
It's happening! Precision access experts are ready to work with you to solve your patient access challenges. Schedule a meeting today: https://lnkd.in/e2ycff3v PRECISIONvalue PRECISIONxtract PRECISIONadvisors #Asembia24
-
-
Asembia starts Monday! Talk to our experts to learn about the right tools and data insights that can help you overcome barriers to market access. Schedule a meeting to learn more: https://lnkd.in/e2ycff3v #patients #payers #providers #Asembia24 #MarketAccess PRECISIONvalue PRECISIONxtract PRECISIONadvisors
-
-
In an ever-evolving biopharma landscape, the quest for real-world evidence (RWE) shines as a guiding light, offering valuable insights into patient outcomes and treatment effectiveness. But what happens when resource constraints cast shadows on this path of discovery? Precision Value & Health’s Ross Maclean sits down with Christophe Segalini and Alexander Büsser to tackle this question head-on in their latest article in PharmaPhorum. Join they as they explore how small biotechs are navigating these challenges with innovative strategies and leveraging technology to redefine RWE generation. Get the insights in the full article: https://lnkd.in/e2GMcWK2 #RWE #RealWorldEvidence #AIinHealthcare #biopharma PRECISIONheor PRECISIONvalue PRECISIONadvisors
-
-
As the EU Joint Clinical Assessment (JCA) inches closer to implementation, understanding its nuances becomes increasingly critical for drug developers. Explore the insights of our team members – Ross Maclean, EVP, HEOR & Medical Affairs, Richard Macaulay, SVP, Global Pricing and Market Access, and Kabirraaj (Kabir) Toor, Director, HEOR Consulting – as we dive into a comprehensive analysis. We unpack not only the JCA’s objectives and challenges but also provide strategies for navigating this transformative landscape. Are you prepared to stay ahead of the curve? Download now and gear up for success in this ever-changing landscape. https://lnkd.in/e7JkDdEH #JCAimplementation #HEOR #marketaccess #healthcarestrategy PRECISIONheor PRECISIONadvisors PRECISIONvalue
-
-
Please join us in congratulating the following team members on their recent promotions! We are incredibly proud of their ongoing dedication and commitment to their work, teams, and clients. ? Becky Andrews, Consultant ? Dominic Currell, Consultant ? Iman Malik, Consultant ? Victor Moran, Consultant ? Bretram Rogers, Consultant ? Chloe Wang, Consultant ? Minsu Kim, Senior Consultant ? William Derrickson, Engagement Manager ? Lauren Drysch, Engagement Manager ? Jordan Page, Engagement Manager ? Kate Kolotourou, Senior Engagement Manager ? Melissa Mendez, Senior Engagement Manager ? Dominika Mészárosová, Senior Engagement Manager ? Akshit Nayar, Senior Director ? Eddie Vogel, Senior Director Congratulations, everyone! We look forward to seeing your continued success in your new roles.
-